Luwy Musey Selected Research

Vaccines

7/2023	Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study.
1/2023	Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
1/2023	Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
1/2022	Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
1/2021	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence.
12/2019	A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
1/2016	Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009.
5/2009	Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults.
7/2003	HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luwy Musey Research Topics

Disease

11	Pneumococcal Infections 12/2023 - 01/2016
4	Pain (Aches) 01/2023 - 10/2021
4	Infections 12/2019 - 07/2003
2	Fatigue 01/2023 - 03/2022
1	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2023
1	Fever (Fevers) 07/2023
1	Injection Site Reaction 01/2023
1	Diphtheria 01/2023
1	Hepatitis B 01/2023
1	Hypersensitivity (Allergy) 01/2023
1	Tetanus 01/2023
1	Whooping Cough (Pertussis) 01/2023
1	Myalgia 01/2023
1	Pneumococcal Pneumonia 01/2021
1	Spontaneous Abortion (Miscarriage) 12/2019
1	Virus Diseases (Viral Diseases) 12/2019
1	Measles 01/2016
1	Rubella (German Measles) 01/2016
1	Mumps 01/2016
1	Neoplasms (Cancer) 05/2009

Drug/Important Bio-Agent (IBA)

9	23-valent pneumococcal capsular polysaccharide vaccineIBA 12/2023 - 01/2016
9	VaccinesIBA 07/2023 - 07/2003
4	Conjugate VaccinesIBA 07/2023 - 10/2021
4	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 01/2023 - 01/2021
2	Polysaccharides (Glycans)IBA 01/2023 - 01/2021
2	AntigensIBA 05/2009 - 09/2003
1	gamma- hydroxy- gamma- ethyl- gamma- phenylbutyramide (HEPB)IBA 01/2023
1	Cytomegalovirus VaccinesIBA 12/2019
1	Viral AntigensIBA 12/2019
1	AntibodiesIBA 12/2019
1	Neutralizing AntibodiesIBA 01/2019
1	ImmunosorbentsIBA 01/2016
1	EnzymesIBA 01/2016
1	Rubella VaccineIBA 01/2016

Therapy/Procedure

1	Therapeutics 05/2009
1	Immunotherapy 05/2009